3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Sarcoma
3
Urinary Bladder Neoplasms
2
Pancreatic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Ewing
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Male Urogenital Diseases
1
Lymphedema
1
Lung Neoplasms
1
Gallbladder Neoplasms
1
Financial Stress
1
Female Urogenital Diseases
1
Endometrial Neoplasms
1
Encopresis
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
4
enfortumab vedotin
3
Gemcitabine
3
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
testosterone 17 beta-cypionate
1
temsirolimus
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
dodecyl maltoside
1
Valproic Acid
1
Testosterone Propionate
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Ringer's acetate
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Mitomycin
1
Methyltestosterone
1
Immunoglobulin G
1
Fluorouracil
1
Etoposide
1
Doxycycline
1
Disulfides
1
Cyclophosphamide
1
Cetuximab
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Radiation Dose Hypofractionation
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled